Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer.
Rui WanYanrong GuoXuezhi HaoZhijie WangJianchun DuanJie WangPublished in: Therapeutic advances in medical oncology (2023)
This study indicated that compared with nab-paclitaxel monotherapy, combined nab-paclitaxel and ICIs failed to improve survival in relapsed SCLC.